Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01313923 · ClinicalTrials.gov registry record · Early Phase 1
Evaluating Sirolimus to Treat Autoimmune Blistering Dermatosis Pemphigus
A Early Phase 1 study, sponsored by University of California, Irvine.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 3
- Enrollment target
NCT01313923 is a Early Phase 1 study that was terminated before completion, run by University of California, Irvine. The registered enrollment target is 3 participants.
The verdict
NCT01313923, a Early Phase 1 study, was terminated before completion, sponsored by University of California, Irvine.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this research is to study alternative treatments for the skin disease pemphigus (a rare autoimmune blistering disorder of the skin) by using sirolimus, an immunosuppressive drug. Immunosuppressive drugs inhibit or prevent the activity of the immune system and are commonly used to treat autoimmune diseases, inflammatory diseases, and organ transplantation rejection.
Interventions
- DRUG Sirolimus (formerly known as Rapamycin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2011-02 |
| Est. Completion | 2014-10 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01313923
The ClinicalTrials.gov registry entry for NCT01313923 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Irvine, which has 368 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sirolimus (formerly known as Rapamycin) is the first listed.
NCT01313923 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01313923 about?
NCT01313923 is a clinical study titled "Evaluating Sirolimus to Treat Autoimmune Blistering Dermatosis Pemphigus". The purpose of this research is to study alternative treatments for the skin disease pemphigus (a rare autoimmune blistering disorder of the skin) by using sirolimus, an immunosuppressive drug. Immunosuppressive drugs inhibit or prevent the activity of the immune system and are commonly used to trea...
What is the current status of trial NCT01313923?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 3 participants. The study started on 2011-02. Estimated completion is 2014-10.
What interventions are being tested in trial NCT01313923?
The interventions under investigation include: Sirolimus (formerly known as Rapamycin) (DRUG).
Who is sponsoring clinical trial NCT01313923?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.